Menumenu
  • Home
  • Resource Library

Resource Library

publications • bibliographies • white papers

All Publications

  • Pioglitazone use and risk of bladder cancer in patients with type 2 diabetes: retrospective cohort study using datasets from four European countriesAbstract

    OBJECTIVE: To evaluate the association between pioglitazone use and bladder cancer risk in patients with type 2 diabetes. DESIGN: Retrospective cohort study using propensity score matched cohorts. SETTINGS: Healthcare databases from Finland, the Neherlands, Sweden, and the United Kingdom. Data comprised country specific datasets of linked records on prescriptions, hospitals, general practitioners, cancer, and deaths

    Korhonen P, Heintjes EM, Williams R, Hoti F, Christopher S, Majak M, Kool-Houweling L, Strongman H, Linder M, Dolin P, Bahmanyar S. BMJ. 2016 354 i3903.
  • Anticoagulant Treatment after VTE in the Netherlands: A Retrospective Cohort StudyAbstract

    Background: The aim of the study was to describe initial anticoagulant treatment after venous thromboembolism (VTE) and relate this to the underlying risk factors, guidelines and recurrence rates.

    Bezemer ID, van den Berg EJ, Herings RMC, Bamber L, Penning-van Beest FJA, Folkerts K, Coppens M. J J Hemato. 2016 2 (2): 030.
  • Useful Interplay Between Spontaneous ADR Reports and Electronic Healthcare Records in Signal DetectionAbstract

    BACKGROUND AND OBJECTIVE: Spontaneous reporting systems (SRSs) remain the cornerstone of post-marketing drug safety surveillance despite their well-known limitations. Judicious use of other available data sources is essential to enable better detecion, strengthening and validation of signals. In this study, we investigated the potential of electronic healthcare records (EHRs) to be used alongside an SRS as an independent system, with the aim of improving signal detection

    Pacurariu AC, Straus SM, Trifiro G, Schuemie MJ, Gini R, Herings R, Mazzaglia G, Picelli G, Scotti L, Peder sen L, Arlett P, van der Lei J, Sturkenboom MC, Coloma PM. Drug Saf. 2015 Dec; 38 (12): 1201-10.
  • Infants born before 32 weeks of gestation or with respiratory disease are most likely to receive palivizumab in the NetherlandsAbstract

    AIM: Palivizumab is reported to be effective in reducing respiratory syncytial virus hospitalisation. Its licensed uses include infants younger than six months of age, born before 35 weeks of gestation or under two years old with congenital heart dsease or bronchopulmonary dysplasia. We redressed lack of research in the Netherlands by studying whether infants who met the licensed indications received the drug

    Kool-Houweling LM, Penning-van Beest FJ, Bezemer ID, van Lingen RA, Herings RM. Acta Paediatr. 2015 Sep; 104 (9): 927-32.
  • Trends in paediatric macrolide use in five European countries-a population-based studyAbstract

    PURPOSE: The study aims to analyse overall as well as subgroup-specific outpatient paediatric macrolide use in five European countries, including time trends of macrolide prescription rates, and to provide potential targets for future interventionsaiming to promote judicious macrolide use. METHODS: Macrolide prescription rates per 1000 person years to paediatric outpatients (

    Holstiege J, Ender s D, Schink T, Innocenti F, Oteri A, Bezemer I, Kaguelidou F, Molokhia M, Poluzzi E, Puccini A, Ulrichsen SP, Sturkenboom MC, Trifiro G, Garbe E. Eur J Clin Pharmacol. 2015 Aug; 71 (8): 991-9.
  • Long term trends in oral antidiabetic drug use among children and adolescents in the NetherlandsAbstract

    AIM: The aim of the study was to document long term trends in oral antidiabetic drug (OAD) use among children and adolescents in the Netherlands. METHODS: A population-based cohort study was conducted using the Dutch PHARMO Database Network. All paients younger than 20 years old with at least one OAD dispensing were identified

    FazeliFarsani S, Souverein PC, Overbeek JA, van der Vorst MM, Knibbe CA, Herings RM, deBoer A, Mantel-Teeuwisse AK. Br J Clin Pharmacol. 2015 Aug; 80 (2): 294-303.
  • Chronic comorbidities in children with type 1 diabetes: a population-based cohort studyAbstract

    OBJECTIVE: To determine the incidence of chronic comorbidities among children with type 1 diabetes (T1D) and to compare incidences with a group of children without diabetes. DESIGN: Population-based cohort study. SETTING: Dutch PHARMO database (199-2010). PATIENTS: All patients (<19 years old) with T1D between 1999 and 2009 (T1D cohort) and a group of age- and sex-matched (ratio: 1-4) children without diabetes (reference cohort)

    FazeliFarsani S, Souverein PC, van der Vorst MM, Knibbe CA, deBoer A, Mantel-Teeuwisse AK. Arch Dis Child. 2015 Aug; 100 (8): 763-8.
  • Antibiotic use varies substantially among adults: a cross-national study from five European Countries in the ARITMO projectAbstract

    PURPOSE: To examine patterns of outpatient and community antibiotic use among adults in five European countries. METHODS: We used healthcare data of 28.8 million adults from six population-based ARITMO project databases to ascertain information onystemic antibiotic use in Denmark (2000-2008), the Netherlands (1999-2010), Italy (2000-2010), the UK (1996-2009), and Germany (2004-2008)

    Mor A, Froslev T, Thomsen RW, Oteri A, Rijnbeek P, Schink T, Garbe E, Pecchioli S, Innocenti F, Bezemer I, Poluzzi E, Sturkenboom MC, Trifiro G, Sogaard M. Infection. 2015 Aug; 43 (4): 453-72.
  • The role of electronic healthcare record databases in paediatric drug safety surveillance: a retrospective cohort studyAbstract

    AIM: Electronic healthcare record (EHR)-based surveillance systems are increasingly being developed to support early detection of safety signals. It is unknown what the power of such a system is for surveillance among children and adolescents. In tis paper we provide estimates of the number and classes of drugs, and incidence rates (IRs) of events, that can be monitored in children and adolescents (0-18 years)

    deBie S, Coloma PM, Ferrajolo C, Verhamme KM, Trifiro G, Schuemie MJ, Straus SM, Gini R, Herings R, Mazzaglia G, Picelli G, Ghirardi A, Peder sen L, Stricker BH, van der Lei J, Sturkenboom MC, consortium Eu-Adr. Br J Clin Pharmacol. 2015 Aug; 80 (2): 304-14.
  • Dispensing of potentially teratogenic drugs before conception and during pregnancy: a population-based studyAbstract

    OBJECTIVE: To study the dispensing of potentially teratogenic drugs in the 12-month period before as well as during pregnancy in the Netherlands. DESIGN: Population-based study. SETTING: A cohort was constructed using a linkage between the PHARMO Dtabase Network and the Netherlands Perinatal Registry (PRN)

    Zomerdijk IM, Ruiter R, Houweling LM, Herings RM, Straus SM, Stricker BH. BJOG. 2015 Jul; 122 (8): 1119-29.